Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), an Israel-based biopharmaceutical company, announced on Tuesday that it has named Liat Halpert as its head of Business Development and Sales.

In the new role, Halpert will concentrate on expanding the business by aiming at European and US-based biotech companies to support further growth of the CDMO business into a significant revenue generator for Scinai and a key partner for small biotechnology companies.

Halpert has experience in pharmaceutical sales and marketing. She has served at Novartis for 14 years, most recently serving as marketing and commercial excellence lead for cell and gene therapies for Central, Southern and Eastern Europe.

Amir Reichman, Scinai's CEO, said: "I am pleased to welcome Liat to Scinai. Her pharmaceutical sales, marketing, and leadership experience, in particular in Israel and Europe, align with our strategic decision to grow Scinai Bioservices CDMO into a trusted provider of drug development services, including for preclinical and clinical trials and GMP manufacturing for clinical supplies."